Photocure Third Quarter 2024 Earnings: Beats Expectations

Photocure (OB:PHO) Third Quarter 2024 Results

Key Financial Results

• Revenue: kr120.2m (up 12% from 3Q 2023).
• Net loss: kr3.47m (loss narrowed by 28% from 3Q 2023).
• kr0.13 loss per share (improved from kr0.18 loss in 3Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Photocure Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 2.3%. Earnings per share (EPS) also surpassed analyst estimates by 52%.

Looking ahead, revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 7.3% growth forecast for the Pharmaceuticals industry in Europe.

Performance of the market in Norway.

The company's shares are down 1.9% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We have a graphic representation of Photocure's balance sheet and an in-depth analysis of the company's financial position.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.